Skip to main content

Table 2 Prevalence of symptoms and incidence of conditions in 31–150 days following SARS-CoV-2 testing among adults and children with positive and negative SARS-CoV-2 test results

From: Association between SARS-CoV-2 infection and select symptoms and conditions 31 to 150 days after testing among children and adults

 

No./total No. (%)

Prevalent symptoms and incident conditions

Non-hospitalized

Hospitalized

Positive

Negative

Positive

Negative

Adults (≥20 years)

 Symptoms outcomes

  At least one symptom

105819/262400 (40.3)

822370/2020829 (40.7)

23989/44926 (53.4)

291712/662295 (44.0)

  Three or more symptoms

17946/262400 (6.8)

148606/2020829 (7.4)

6843/44926 (15.2)

73005/662295 (11.0)

  Fatigue or muscle weakness

17188/262400 (6.6)

126156/2020829 (6.2)

5454/44926 (12.1)

58508/662295 (8.8)

  Shortness of breath

17450/262400 (6.7)

133948/2020829 (6.6)

7562/44926 (16.8)

64494/662295 (9.7)

 Conditions outcomes

  Mental health conditions

14180/188941 (7.5)

116175/1426799 (8.1)

3165/30079 (10.5)

47330/441280 (10.7)

  Chronic kidney disorders

2762/252853 (1.1)

31724/1940517 (1.6)

1874/35031 (5.3)

23936/579705 (4.1)

  Diabetes type 1 or type 2

4245/225157 (1.9)

36944/1778370 (2.1)

2016/29502 (6.8)

19753/533887 (3.7)

  Hematologic disorders

2248/265308 (0.8)

18770/2054644 (0.9)

2082/43284 (4.8)

18122/646387 (2.8)

  Major adverse cardiovascular events

7028/238918 (2.9)

71936/1783138 (4.0)

3980/30945 (12.9)

52227/504033 (10.4)

  Neurological disorders

8478/236441 (3.6)

83539/1791423 (4.7)

3252/34755 (9.4)

44248/542090 (8.2)

  Respiratory diseases

8298/229162 (3.6)

73078/1742318 (4.2)

4463/32125 (13.9)

37561/527227 (7.1)

Children and young adults (0 -19 years)

 Symptoms outcomes

  At least one symptom

15145/58196 (26.0)

134017/511383 (26.2)

1196/2725 (43.9)

32343/91933 (35.2)

  Three or more symptoms

1159/58196 (2.0)

10534/511383 (2.1)

227/2725 (8.3)

4841/91933 (5.3)

  Fatigue or muscle weakness

1338/58196 (2.3)

10324/511383 (2.0)

166/2725 (6.1)

3674/91933 (4.0)

  Shortness of breath

1345/58196 (2.3)

11730 /511383 (2.3)

179/2725 (6.6)

3676 / 91933 (4.0)

  1. At least one symptom refers to at least one ICD-10 code: fatigue or muscle weakness, shortness of breath, cough, change in bowel habits, abdominal pain, headache, cognitive disorders, disorders of taste and smell, non-cardiac chest pain, heart rate abnormalities, sleep disorders, and myalgia and arthralgia. Three or more symptoms refer to at least 3 ICD-10 diagnosis codes for one or more symptoms. Mental health conditions include anxiety, depression, other mood disorders, overdose, psychosis, substance misuse, and suicide ideation/attempts. Chronic kidney disorders include chronic kidney disease and nephrotic and nephritic syndromes. Hematologic disorders include other venous thromboembolism and pulmonary embolism. Major adverse cardiovascular events include arrythmias, heart failure, intracerebral hemorrhage, ischemic infarction, myocardial infarction, myocarditis, subarachnoid hemorrhage, transient ischemic attack or other stroke. Neurological disorders include ataxia, autonomic dysfunction, dementia, encephalitis, myoneural disorders, parkinsonism, peripheral nerve disorders, and seizures. Respiratory disease includes asthma, chronic bronchitis, chronic obstructive pulmonary disease, hypoxemia, interstitial lung disease, pulmonary edema, pulmonary hypertension, and chronic respiratory failure. Condition outcomes were assessed among adults only as these conditions are extremely rare among children. No. is the number of persons with the given symptom or condition diagnosed 31 to 150 days after SARS-CoV-2 testing. For condition outcomes, we excluded patients who also had a condition in 540–31 days prior to the index test date; total No. = number of persons meeting the inclusion criteria. Therefore, total denominators of condition outcomes vary for each row because of removal of persons with conditions in the baseline period
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us